Shots:

• The submissions are based on P-III GO-VIVA study involves assessing of SIMPONI ARIA in 127 patients aged 2-17yrs. with active pJIA having arthritis in 5or more joints- despite current treatment with methotrexate for at least two mos.
• The focus of the study is to evaluate PK safety & efficacy of the therapy in pediatric pJIA patients and the data of pJIA patients were compared to its P-III GO-FURTHER study of SIMPONI ARIA in adult patients with RA and the data of jPsA patients was compared to the results of P-III GO-VIBRANT study in adults patients with PsA
• SIMPONI ARIA is an anti-TNF-alpha mAb targeting both soluble and transmembrane bioactive forms of human TNF-alpha and is administered via a 30-min infusion- approved for moderately to severely active RA- active PsA or active AS

Click here to­ read full press release/ article 

Ref: J&J | Image: Jassen